Company intelligence / Profile preview

Bracco Suisse

Plan-les-Ouates, Geneva, Switzerland

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Bracco Suisse SA is a specialized subsidiary of the Bracco Group focused on the research, development, and manufacturing of ultrasound contrast agents. Based in Plan-les-Ouates, Switzerland, the company is the global production site for SonoVue (marketed as Lumason in the United States), a leading sulfur hexafluoride microbubble contrast agent. The facility integrates advanced R&D laboratories with high-tech manufacturing suites to support the global supply of contrast media for echocardiography and radiology. Beyond diagnostic imaging, Bracco Suisse explores the therapeutic potential of microbubbles, including targeted drug delivery and ultrasound-mediated therapy.

Therapeutic areas: CardiovascularNephrologyGastroenterology
Modalities: MicrobubbleContrast agentDevice
Industry: Medical Imaging

Beyond the preview

Go deeper on Bracco Suisse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bracco Suisse.

Explore the full profile